FDA Clearance Tracker · K143750
MEG-2B Blood Glucose Monitoring System, MEG-2B Pro Blood Glucose Monitoring System
Last checked: Nov 19, 2026Latest source record: May 7, 2015 (this decision)Source: openFDAMethods & limitations
Decided
May 7, 2015
Substantially Equivalent
Time to decision
127 days
Received Dec 31, 2014. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K143750
- Device name
- MEG-2B Blood Glucose Monitoring System, MEG-2B Pro Blood Glucose Monitoring System
- Applicant
- Apex BioTechnology Corp.
- Applicant location
- Hsinchu, TW
- Received
- Dec 31, 2014
- Decided
- May 7, 2015
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Glucose Oxidase, Glucose (CGA)
- Device class
- Class II
- Regulation
- 21 CFR 862.1345
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code CGA. The earliest in FDA's data is K760347, decided Oct 5, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K143750
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Apex BioTechnology Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K242209 · Decided Apr 4, 2025 · 249 days after receipt
Device type: Uric Acid Test System For At Home Prescription Use (PTC) · Laboratory Medicine & Pathology
K222234 · Decided Dec 21, 2022 · 148 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
K220421 · Decided Nov 4, 2022 · 263 days after receipt
Device type: System, Test, Blood Glucose, Over The Counter (NBW) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.